Loading
Anemia secondary to chronic kidney disease, primarily caused by inadequate erythropoietin production by damaged kidneys, managed with ESAs and iron supplementation.
Renal anemia develops due to insufficient erythropoietin (EPO) production by peritubular fibroblasts in the kidneys as CKD progresses. Other contributing factors include functional iron deficiency (hepcidin-mediated iron blockade), inflammation (cytokine-mediated suppression), reduced red cell lifespan due to uremia, and blood loss (especially in HD patients from dialyzer retention and laboratory draws). Management follows KDOQI Anemia Guidelines (2012): iron repletion before ESA initiation (ferritin >200 ng/mL, TSAT >20%); ESA initiation when Hb <10 g/dL; target Hb range 10-11.5 g/dL (avoid >13 g/dL per TREAT trial safety data). Hyporesponsiveness to ESA requires investigation for iron deficiency, inflammation, hyperparathyroidism, malignancy, and medication non-adherence.
A progressive condition characterized by gradual loss of kidney function over months or years, classified into 5 stages based on eGFR.
The final stage of chronic kidney disease (Stage 5, eGFR <15) where kidneys can no longer sustain life without dialysis or transplantation.
The automated connection between laboratory analyzers and the clinical information system for electronic ordering, sample tracking, result capture, quality control, and critical value alerting.
Advertisement
ZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.